DermTech (DMTK) Reports Positive Topline Results From a Study Evaluating the DermTech Melanoma Test Across All Skin Types streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
- Trust 2 Study confirms negative predictive value of 99.7% for the foundational gene expression assay
- Optional TERT promoter mutation testing does not significantly alter sensitivity, NPV or.
/PRNewswire/ WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022.